New and Emerging Treatments for Diabetic Eye Disease
How Diabetic Eye Disease Is Treated Today
Several well-established treatments are currently used to protect vision in people with diabetic eye disease. Understanding how they work helps set the stage for appreciating what newer options are trying to improve upon.
Anti-VEGF medicines block a protein called vascular endothelial growth factor (VEGF), which is a signal the body uses to grow new blood vessels. In diabetic eye disease, the body produces too much of this signal, leading to leaky vessels, swelling in the central part of the retina (called the macula), and abnormal vessel growth. A specialist injects the medicine directly into the eye, where it can reduce swelling and slow disease progression. Many patients start with monthly injections and then move to longer intervals once the eye responds well.
Steroids calm inflammation and can reduce swelling in the macula when anti-VEGF treatment alone is not sufficient. Some steroid treatments are given as injections, while others come as small implants placed inside the eye that release medicine slowly over several months. Because steroids can raise eye pressure and speed up cataract development in some people, your care team carefully weighs the benefits against the risks.
Laser treatment uses focused light to seal leaking blood vessels or to slow the growth of abnormal vessels on the retina. For many years, laser was the primary way to protect vision in advanced diabetic retinopathy, and it is still used today. It is sometimes combined with injections, especially when swelling keeps returning after injections alone.
When bleeding inside the eye does not clear on its own, or when scar tissue begins pulling on the retina, a surgical procedure called a vitrectomy may be recommended. During this procedure, the gel inside the eye is removed and replaced with a clear fluid or gas, and scar tissue is carefully peeled away from the retina. Recovery takes several weeks, and most patients continue to need injections or laser after surgery to keep the disease stable.
Current treatments work well, but keeping up with them can be difficult. Monthly visits, repeated injections, and travel for care create real burdens for patients, and missed appointments can lead to vision loss that may not be reversible. Researchers are working to develop treatments that last longer, reach more people, and feel less demanding than frequent injections.
Higher-Dose and Longer-Lasting Anti-VEGF Options
One of the most active areas of research focuses on making anti-VEGF treatments last longer so that patients need fewer visits each year. Several approaches are already approved or in late-stage testing.
One strategy for spacing out injections is to use a stronger dose of the same medicine. A higher dose may stay active in the eye longer, allowing a specialist to schedule visits further apart. A higher-dose form of one anti-VEGF medicine has been approved for diabetic macular edema, the swelling in the center of the retina caused by diabetes.
In large clinical studies of higher-dose anti-VEGF for diabetic macular edema, patients received a higher dose every twelve or sixteen weeks after an initial loading phase. Their vision results were compared with patients on the standard dose given every eight weeks. Both groups improved vision in similar ways, and most patients on the longer schedules were able to stay on those extended intervals, suggesting fewer visits without sacrificing results.
Biosimilars are carefully manufactured copies of approved biologic medicines that have already been studied in patients. Several biosimilars of common anti-VEGF medicines have been approved, giving specialists more treatment choices and potentially lowering costs over time. Regulators verify that biosimilars work and behave in the body in very similar ways to the original medicines.
For someone who has been receiving monthly injections, moving to a treatment given every three or four months can create meaningful change in daily life. Fewer visits mean less time away from work, less travel, and fewer days spent managing a sore eye afterward. Your care team will continue to monitor imaging between visits to confirm that the eye is staying stable on the longer schedule.
Higher-dose injections are not the right fit for every patient. Some eyes still need frequent treatment to stay free of swelling, and some individuals experience side effects that limit how often treatment can be given. Long-term safety data over many years is still being gathered, and researchers continue to study how higher doses affect eye pressure and other measures over time.
Sustained Delivery Systems for the Eye
Sustained delivery systems are small devices designed to release medicine continuously inside the eye, reducing the need for separate injections at each visit. This approach is being actively studied for diabetic eye disease.
A sustained delivery device is a small implant placed in the white part of the eye during a short procedure. It slowly releases medicine over several months and can be refilled in the office when the supply runs low. The goal is to maintain a steady level of treatment without requiring a separate injection every visit.
Injections given weeks apart naturally produce peaks and valleys in the amount of medicine inside the eye. A sustained delivery system may keep those levels more consistent, which could mean better control of swelling and abnormal vessel growth between visits. For patients who have difficulty attending the clinic frequently, a refill every several months may also be easier to plan around.
One sustained delivery system was first studied in age-related macular degeneration, another retinal disease that uses the same anti-VEGF medicines. Research programs are now examining whether the same approach works for diabetic macular edema and diabetic retinopathy. Early findings suggest that stable drug levels inside the eye are achievable, but the right refill timing for diabetic disease is still being determined.
Sustained delivery may offer real relief from frequent injections, but it comes with its own considerations. The procedure to place the device carries a small risk of infection, bleeding, or movement of the implant. A specialist will review these tradeoffs and determine whether this approach is appropriate based on your eye anatomy and overall health.
Eye Drop Treatments in Development
The idea of treating diabetic eye disease with drops instead of needles is appealing to many patients, and researchers are working hard to make it possible. However, significant scientific hurdles remain.
Standard eye drops are designed to treat the front of the eye. The retina sits at the back, behind layers of tissue and fluid that block nearly all of the medicine from a conventional drop from reaching it. This is why diabetic eye disease has required injections for so long, and it is the central challenge for any drop currently under study.
Researchers are exploring several ways to help medicine travel through the eye and reach the retina. Some drops use very small particles that carry the drug through tissue, while others modify the chemistry of the drug itself so that more of it is absorbed. The medicines being tested include anti-VEGF molecules, drugs that target other growth signals, and anti-inflammatory compounds.
Early human studies of some retinal drop formulations have demonstrated that medicine can reach the back of the eye in measurable amounts, which is a meaningful step forward. A few studies have shown modest improvements in swelling or in early disease markers. Larger trials are needed to confirm whether the benefit is strong enough to replace or delay injections in practice.
If an effective drop is approved, patients could use it at home without needing a needle. This could make earlier treatment possible for more people, including those who avoid injections out of fear or who have difficulty getting to a clinic regularly. Drops would most likely be used as part of a stepped care plan, with injections still reserved for more advanced disease stages.
Pills Being Studied for Diabetic Eye Disease
Oral medicines, meaning pills taken by mouth, offer another path to treating diabetic eye disease without injections. Several drugs are now being studied in clinical trials at various stages.
A pill follows a different route than an injection. The medicine is absorbed in the digestive system, enters the bloodstream, and must then cross the barrier between blood vessels and the retina to reach the back of the eye. Researchers are identifying drugs that survive this journey and arrive at the retina in amounts that could make a meaningful difference.
Some oral drugs being studied target VEGF through mechanisms different from existing injections. Others aim at related biological signals, including growth factors and molecules involved in inflammation and cellular stress. The hope is that reaching more than one part of the disease process at once may slow progression without requiring daily eye treatment.
Several oral drugs have progressed into mid-stage and late-stage trials for diabetic retinopathy and diabetic macular edema. Some are being studied in people with mild or moderate retinopathy who do not yet need injections. Others are being tested as an add-on for patients who still have swelling despite current standard care.
An oral medicine is unlikely to fully replace injections for advanced disease in the near future. It may, however, give people with early changes a way to slow disease progression and lower the chance of advancing to a stage that requires injections. Pills may also help patients who get only partial relief from injections by addressing parts of the disease that injections do not target.
Gene Therapy Approaches
Gene therapy represents one of the most exciting long-term possibilities in retinal care. Rather than delivering medicine repeatedly, the goal is to teach the eye to produce its own treatment from within.
Gene therapy uses a modified, harmless virus to carry genetic instructions into cells inside the eye. Once those instructions are in place, the cells begin producing a protein that the eye needs more of. For diabetic eye disease, the goal is to help cells in the eye make their own anti-VEGF protein on an ongoing basis after a single treatment.
A single injection of gene therapy could potentially turn cells in the retina or the white of the eye into a continuous source of anti-VEGF. Instead of repeated injections every few months, a patient might receive one treatment and maintain stable protection inside the eye for an extended period. This concept is currently being studied in early and mid-stage human trials.
Several gene therapy programs are in human clinical trials for diabetic retinopathy and related retinal diseases. Some deliver the therapy into the gel of the eye, while others place it beneath the retina during a brief surgical procedure. Early results have shown that some patients can go many months without needing rescue injections after a single gene therapy dose.
Because gene therapy creates a lasting change inside the eye, safety is monitored very closely over time. Researchers watch for inflammation, changes in eye pressure, and any signs that protein production becomes too high or too low. The eye has so far been a relatively safe environment for gene therapy research because it is small, accessible, and easier to observe than other parts of the body. Patients in trials are typically followed for years after their treatment.
Other Promising Research Directions
Beyond anti-VEGF advances and gene therapy, researchers are exploring additional strategies that could improve outcomes for people with diabetic eye disease. These include targeting inflammation, regenerating damaged tissue, and using technology to detect disease earlier.
Diabetes does not only damage blood vessels in the eye. It also triggers inflammation that causes vessels to leak and damages retinal cells over time. Several research programs are testing drugs that calm specific parts of this inflammatory process, including the complement system, which is a chain of immune proteins. The goal is to protect the retina before swelling and bleeding ever begin.
Some researchers are studying whether cells grown in a laboratory setting can replace retinal cells damaged by diabetes. Other work looks at growth factors that may help the retina repair itself over time. These approaches are still in early stages, being tested first in animal models and small human studies, and are not yet part of routine clinical care.
Advanced imaging tools and computer programs that use artificial intelligence are helping specialists identify diabetic eye disease earlier than ever before. Some tools can analyze a photograph of the back of the eye and flag warning signs in seconds. Catching disease earlier often means simpler treatment and better long-term vision outcomes.
Combining two or more treatments may work better than any single approach for some patients. For example, a longer-lasting injection may be paired with an oral drug that targets inflammation, or laser may be added to injections in eyes where swelling is difficult to control. Clinical trials are currently testing which combinations provide the best vision results with the fewest visits required.
What These Advances Mean for You
Learning about new treatments can raise questions about your own care. Understanding how to apply this information to your situation is just as important as the science itself.
If you have read about a new treatment and wonder whether it applies to you, the best step is to bring it up at your next appointment. Your specialist knows your eye health history, your other medical conditions, and your response to current treatment, and can explain what is realistic for you today versus what is still years away from being widely available.
Clinical trials are how new diabetic eye disease treatments are tested in people. Joining a trial may offer access to a treatment not yet approved, and it also helps advance care for future patients. Your specialist may know about active trials in your area, and public clinical trial databases allow you to search by condition, location, and disease stage.
- Ask about trials that match your stage of diabetic eye disease
- Find out what visits, imaging, and risks are involved before enrolling
- Confirm what care you would receive if the new treatment did not work for you
Research is encouraging, but the most important step you can take today is to follow your current treatment plan consistently. Skipping injections or delaying visits can allow swelling to return, and some vision loss from diabetic eye disease cannot be reversed once it occurs. Keeping blood sugar, blood pressure, and cholesterol well controlled also plays a meaningful role in slowing disease progression.
New eye treatments often take many years to move from early studies into widespread clinical use. Some options discussed here may reach more practices within the next few years, while others are still much further away. A treatment showing early promise in a small study today may not be broadly available for a decade, even if the initial results are encouraging.
Frequently Asked Questions
These questions address some of the more specific concerns patients often have when learning about emerging diabetic eye disease treatments.
No eye drop has been approved yet for diabetic retinopathy or diabetic macular edema. The research is meaningful but still in early phases, and proving that a drop improves vision as reliably as an injection requires large, long-term studies. If a drop is eventually approved, it will most likely be introduced for early-stage disease first, with injections continuing to be the standard for more advanced cases.
Waiting is rarely a safe choice when treatment has already been recommended for your eye. Diabetic eye disease can progress quietly, and some damage cannot be undone once it occurs. Starting current care does not prevent you from adding or switching to a new approved option later if one becomes available and fits your situation.
Gene therapy does make lasting changes to cells inside the eye, which is why safety monitoring in trials is very thorough and ongoing. Researchers track inflammation, eye pressure, and immune responses carefully, and trial participants are followed for years after a single dose. The eye has shown a relatively favorable safety profile in gene therapy research so far, but this area of medicine is still maturing and long-term data continues to be collected.
Your retina specialist is a practical first resource, since many specialists are aware of trials enrolling in their area. Public databases of clinical trials allow you to search by diagnosis, location, and phase of study. Before making a decision, ask about the time commitment involved, what happens if you need to stop, and whether your standard care would continue alongside the trial treatment.
Coverage depends on whether a treatment has received regulatory approval, the specific insurance plan, and whether a treatment is considered medically necessary for your diagnosis. Approved medicines, including newer higher-dose anti-VEGF options and biosimilars, are generally reviewed by insurance in the same way as other approved medicines. Treatments still in clinical trials are typically provided at no charge to participants but are not billed through insurance. It is worth discussing cost and coverage with your care team before starting any new treatment.
Stability is a good sign, and any change to your treatment schedule should be made thoughtfully. Longer-acting options may be appropriate for patients whose eyes are well controlled, but the decision depends on what your imaging shows, how your vision has responded, and whether the longer-acting option is approved for your specific diagnosis. This is a conversation worth having with your specialist at your next visit rather than making a change on your own.
Expert Retinal Care Close to Home
At Retina Associates of Greater Philadelphia, our team of specialists is dedicated to providing expert, up-to-date care for diabetic eye disease across our five locations in the greater Philadelphia and Southern New Jersey area. We stay current with advances in retinal medicine so that our patients have access to proven treatments and thoughtful guidance about what is on the horizon. We invite you to schedule a visit and work with our team to protect your vision for the long term.
Extremely impressed by entire staff. Dr. Linares is also excellent. Very professional and eager to answer all your questions.
PAULA Lisicki
Having been a patient of Dr Kleiner for decades. I can attest to the professionalism and knowledge that he brings to his patients.
Carolee Bergey
Fantastic! All staff, starting from the front desk all the way to Dr. Greene, are very friendly and professional. Thank you for the good job you do every day.
William Wolff
Dr Linares is an amazing Doctor and a caring person. He has saved my vision on multiple occasions. I recommend Dr Linares wholeheartedly
Stanley Henderson
Dr Kleiner and his staff are great. Not pleasant getting needles in you eye but they make it a nicer experience.
marlene malandrino